No Data
No Data
Volume change rate ranking (10 o'clock) - The Imperial Hotel, Feed One, etc. ranked in.
*In the volume change rate ranking, you can understand the interests of market participants, such as trends in trading activities, by comparing the average trading volume for the past 5 days with the trading volume on the day of the publication. Top volume change rate [as of August 26, 10:32] (compared to the average trading volume for the past 5 days) Stock code Company name Volume 5-day average volume Volume change rate Stock price change rate<133A> GX Super Short Rice 156,450 18,888.661 265.98% -0.0*
Volume Change Rate Ranking (9:00 am) - Fanpep, MagMagu, etc. ranked in
In the volume change rate ranking, you can understand the market participants' interests such as trend of speculation by comparing the average volume of the past 5 days with the volume on the delivery day. Top Volume Change Rates [As of August 22, 9:32] (Comparison with 5-day average volume) Stock Code Stock Name Volume 5-day Average Volume Volume Change Rate Price Change Rate <7857> Seki 400 107185.08 299.34% 0% <8836>
Volume change rate ranking (10 o'clock) - Korowaido, Career DC, etc. ranked in.
In the volume change ratio ranking, by comparing the volume of the last 5 days with the volume on the delivery day, you can understand the market participant's interest in trends such as stock picking. Top gainers in volume change ratio [As of 10:32 on August 21] (comparison with average volume of the last 5 days) Stock code Stock name Volume Average volume of last 5 days Volume change ratio Change in stock price <7616> Color Wide 2849400 522640.2 254.55% -0.0
Promoting pipeline expansion through joint research in the first quarter of Nano MRNA, adding a contract model.
On the 9th, NANO MRNA <4571> announced its consolidated financial results for the first quarter of the 2025 fiscal year (April-June 24). It did not record revenue (the same period last year had revenue of 0.058 billion yen), had an operating loss of 0.189 billion yen (loss of 0.304 billion yen in the same period last year), had an ordinary loss of 0.155 billion yen (loss of 0.285 billion yen in the same period last year), and had a quarterly net loss attributable to parent company shareholders of 0.156 billion yen (loss of 0.285 billion yen in the same period last year). In this first quarter, it shifted from previous collaborative and drug discovery biotech venture models.
Nano mRNA has signed a joint research agreement with Senshu Pharmaceutical to develop mRNA drugs for ophthalmic diseases.
NANO MRNA <4571> announced on the 9th that it has entered into a joint research agreement with Chijyu Pharmaceutical on mRNA drug discovery targeting ophthalmic diseases. The company specializes in non-clinical development of mRNA drug discovery and has created valuable IP. Chijyu Pharmaceutical is a specialty pharma in the field of ophthalmology with unique ideation skills and research and development. Both companies have been conducting basic research on the creation of eye disease treatments using mRNA. This time, they are exploring the creation of mRNA drugs for ophthalmic medicine targets.
Is the dominant buying trend steady and has high expectations for the settlement period?
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to show a steady development. In the US stock market on the weekend of the previous week, the Dow Jones Industrial Average rose by 51.05 dollars (+0.13%) in the absence of the Tokyo market for three consecutive holidays. While the pessimistic view of economic slowdown due to comments from financial officials spread and supported stock prices, the upward trend was heavy ahead of the announcement of important inflation indicators in the following week. On the 12th, the Dow Jones average fell for the third consecutive day, with a decline of 140.53 dollars (-0.36%) to 39,357.01 dollars. Irrelevant content was cut off in the original text.
No Data